Sanofi India Recommends Final Dividend of ₹48; Total Dividend ₹123 for FY25
Sanofi India's Board approved FY25 Audited Financial Results and recommended a final dividend of ₹48 per share, bringing the total dividend for FY25 to ₹123 per share. The company also announced key director appointments: Mrs. Rajani Kesari as Independent Director from April 1, 2026, and Ms. Sudipta Chakraborty as Whole-time Director from March 1, 2026. Mr. Rodolfo Hrosz resigned as Non-Executive Director, effective February 28, 2026.
The dividend recommendation and changes in directorship are significant for the company's governance and shareholder returns, impacting investor sentiment and potentially the company's strategic direction.
The announcement includes a positive outcome regarding dividend declaration and key management appointments, which are generally viewed favorably by investors.
Sanofi India Limited announced the outcome of its Board Meeting held on February 25, 2026. The Board approved the Audited Financial Results for the Quarter and Financial Year ended December 31, 2025. The Statutory Auditors, M/s Price Waterhouse & Co. Chartered Accountants LLP, issued an audit report with an unmodified opinion.
The Board recommended a final dividend of ₹48 per equity share of face value ₹10, subject to shareholder approval at the 70th Annual General Meeting. This is in addition to the interim dividend of ₹75 per equity share declared on October 29, 2025. The total dividend for the financial year 2025 amounts to ₹123 per equity share.
Key changes in directorships were also announced. Mrs. Rajani Kesari has been approved as an Additional Director and Independent Director for a term of five years, effective April 1, 2026. Mr. Rodolfo Hrosz resigned as Non-Executive Director, effective February 28, 2026. Ms. Sudipta Chakraborty has been approved as an Additional Director and Whole-time Director for a term of three years, effective March 1, 2026, and will also serve as Key Managerial Personnel and Senior Management Personnel.
The financial results for the year ended December 31, 2025, show total income of ₹18,571 crore and profit before tax of ₹4,447 crore. For the quarter ended December 31, 2025, total income was ₹4,226 crore and profit before tax was ₹830 crore. The company's balance sheet as of December 31, 2025, shows total assets of ₹12,548 crore and total equity of ₹7,492 crore.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.